Half-year report · HY

Period2025-04-01 → 2025-09-30
Filed2025-11-06
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥1.03T2025-04-01 → 2025-09-30Cons.Revenue IFRS
Revenue¥1.91T2024-04-01 → 2025-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥935.6bn2024-04-01 → 2024-09-30Cons.Revenue IFRS
Operating income¥199.4bn2025-04-01 → 2025-09-30Cons.Operating profit loss IFRS
Operating income¥93.7bn2024-04-01 → 2024-09-30Cons.Operating profit loss IFRS
Profit before tax¥194.6bn2025-04-01 → 2025-09-30Cons.Profit loss before tax IFRS
Profit before tax¥31.2bn2024-04-01 → 2025-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥89.0bn2024-04-01 → 2024-09-30Cons.Profit loss before tax IFRS
Net income (owners)¥147.6bn2025-04-01 → 2025-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥50.7bn2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥73.5bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥147.6bn2025-04-01 → 2025-09-30Cons.Profit loss IFRS
Net income¥73.5bn2024-04-01 → 2024-09-30Cons.Profit loss IFRS
Total assets¥3.45Tat 2025-09-30Cons.Assets IFRS
Total assets¥3.34Tat 2025-03-31Cons.Assets IFRS
Total assets¥3.46Tat 2024-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥1.84Tat 2025-09-30Cons.Liabilities IFRS
Total liabilities¥1.83Tat 2025-03-31Cons.Liabilities IFRS
Net assets / equity¥1.61Tat 2025-09-30Cons.Equity IFRS
Net assets / equity¥1.51Tat 2025-03-31Cons.Equity IFRS
Net assets / equity¥1.53Tat 2024-09-30Cons.Equity IFRS
Net assets / equity¥1.60Tat 2024-03-31vCons.Equity IFRS
Equity (owners)¥1.61Tat 2025-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.51Tat 2025-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.53Tat 2024-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥287.1bnat 2025-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥188.4bnat 2025-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥293.0bnat 2024-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥335.7bnat 2024-03-31vCons.Cash and cash equivalents IFRS
Operating cash flow¥282.6bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥194.5bn2024-04-01 → 2025-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥77.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥30.2bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥89.4bn2024-04-01 → 2025-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥55.7bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥155.8bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥261.4bn2024-04-01 → 2025-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥66.3bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥82.442025-04-01 → 2025-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥28.352024-04-01 → 2025-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥41.062024-04-01 → 2024-09-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥82.172025-04-01 → 2025-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥28.242024-04-01 → 2025-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥40.912024-04-01 → 2024-09-30Cons.Diluted earnings loss per share IFRS
Equity ratio46.7%at 2025-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio45.3%at 2025-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio44.2%at 2024-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 637
ItemContextValueUnit
Interest and dividends received inv cf IFRSInterimDuration2744000000JPY
Other inv cf IFRSPrior1InterimDuration-18667000000JPY
Other inv cf IFRSInterimDuration16023000000JPY
Net cash provided by used in investing activities IFRSPrior1InterimDuration-55732000000JPY
Net cash provided by used in investing activities IFRSInterimDuration-30200000000JPY
Increase decrease in short term borrowings and commercial papers fin cf IFRSPrior1InterimDuration-159939000000JPY
Increase decrease in short term borrowings and commercial papers fin cf IFRSInterimDuration-65515000000JPY
Proceeds from issuance of bonds and long term borrowings fin cf IFRSPrior1InterimDuration200000000000JPY
Proceeds from issuance of bonds and long term borrowings fin cf IFRSInterimDuration-JPY
Redemption of bonds and repayments of long term borrowings fin cf IFRSPrior1InterimDuration-26037000000JPY
Redemption of bonds and repayments of long term borrowings fin cf IFRSInterimDuration-25501000000JPY
Payments for purchase of treasury shares fin cf IFRSPrior1InterimDuration-6958000000JPY
Payments for purchase of treasury shares fin cf IFRSInterimDuration-728000000JPY
Dividends paid to owners of parent fin cf IFRSPrior1InterimDuration-62759000000JPY
Dividends paid to owners of parent fin cf IFRSInterimDuration-66241000000JPY
Repayments of lease obligations fin cf IFRSPrior1InterimDuration-5699000000JPY
Repayments of lease obligations fin cf IFRSInterimDuration-7775000000JPY
Other fin cf IFRSPrior1InterimDuration-4867000000JPY
Other fin cf IFRSInterimDuration9973000000JPY
Net cash provided by used in financing activities IFRSPrior1InterimDuration-66259000000JPY
Net cash provided by used in financing activities IFRSInterimDuration-155788000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1InterimDuration1886000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSInterimDuration2071000000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1InterimDuration-42694000000JPY
Net increase decrease in cash and cash equivalents IFRSInterimDuration98682000000JPY
Cash and cash equivalents IFRSPrior2YearInstant335687000000JPY
Cash and cash equivalents IFRSPrior1YearInstant188372000000JPY
Cash and cash equivalents IFRSPrior1InterimInstant292993000000JPY
Cash and cash equivalents IFRSInterimInstant287054000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の5第1項の表の第1号
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2025-11-06
Semi annual accounting period cover pageFilingDateInstant
Original text (Japanese)第21期中 (自 2025年4月1日 至 2025年9月30日)
Company name cover pageFilingDateInstant
Original text (Japanese)アステラス製薬株式会社
Company name in english cover pageFilingDateInstantAstellas Pharma Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長 岡村 直樹
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都中央区日本橋本町二丁目5番1号
Telephone number address of registered headquarter cover pageFilingDateInstant03 (3244) 3000
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)コーポレートコントローラーコーポレートアカウンティング グループリーダー 藤田 康博
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都中央区日本橋本町二丁目5番1号
Telephone number nearest place of contact cover pageFilingDateInstant03 (3244) 3000
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)コーポレートコントローラーコーポレートアカウンティング グループリーダー 藤田 康博
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE00920
Fund codeFilingDateInstant-
Security codeFilingDateInstant45030
Filer name in japaneseFilingDateInstant
Original text (Japanese)アステラス製薬株式会社
Filer name in englishFilingDateInstantAstellas Pharma Inc.
Fund name in japaneseFilingDateInstant-

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2025-03-31pass
balance sheet identityconsolidated 2025-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2025-04-01/2025-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2025-04-01/2025-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2025-04-01/2025-09-30pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsconsolidated 2025-09-30pass